PDCD1 and non-small cell lung carcinoma: In addition, the development of programmed cell death 1 (PD-1)/PD-1 ligand 1 (PD-L1) checkpoint inhibitors has changed the pattern of non-small cell lung cancer treatment and achieved certain therapeutic effects (5).